Epirubicin/Vinorelbine vs Pegylated Liposomal Doxorubicin/Vinorelbine for Advanced Breast Cancer
Author Information
Author(s): Vici Patrizia, Colucci Giuseppe, Giotta Francesco, Sergi Domenico, Filippelli Gianfranco, Perri Pasquale, Botti Claudio, Vizza Enrico, Carpino Armando, Pizzuti Laura, Latorre Agnese, Giannarelli Diana, Lopez Massimo, Di Lauro Luigi
Primary Institution: Regina Elena National Cancer Institute, Rome, Italy
Hypothesis
To evaluate the activity and tolerability of two anthracycline-containing regimens as first-line treatment for anthracycline-naïve relapsed breast cancer patients.
Conclusion
Both anthracycline-containing regimens evaluated in the present study seem to be active and with satisfactory tolerability in anthracycline-naïve relapsed breast cancer patients.
Supporting Evidence
- Responses were 42.6% for arm A and 52% for arm B.
- Median progression free survival was 10.7 months in arm A and 8.8 months in arm B.
- Median overall survival was 34.6 months in arm A and 24.8 months in arm B.
- Both treatment regimens were well tolerated with manageable toxicity.
Takeaway
This study looked at two types of chemotherapy for breast cancer and found that both worked well and were tolerated by patients.
Methodology
Patients with relapsed breast cancer not previously treated with adjuvant anthracyclines were randomly assigned to receive either epirubicin/vinorelbine or pegylated liposomal doxorubicin/vinorelbine.
Limitations
The study did not include a formal comparison between the two treatment arms.
Participant Demographics
Median age was 63 years for arm A and 61 years for arm B, with a mix of premenopausal and postmenopausal women.
Statistical Information
Confidence Interval
95% CI 29.3%-55.9% for arm A and 95% CI 38.2%-65.8% for arm B.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website